Yoshihisa Akiomi, Takiguchi Mai, Kanno Yuki, Sato Akihiko, Yokokawa Tetsuro, Miura Shunsuke, Abe Satoshi, Misaka Tomofumi, Sato Takamasa, Suzuki Satoshi, Oikawa Masayoshi, Kobayashi Atsushi, Yamaki Takayoshi, Kunii Hiroyuki, Nakazato Kazuhiko, Suzuki Hitoshi, Saitoh Shu-Ichi, Takeishi Yasuchika
Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan
Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.
J Am Heart Assoc. 2017 May 16;6(5):e005110. doi: 10.1161/JAHA.116.005110.
It has been recently reported that histamine H receptor antagonists (H2RAs) are associated with impairment of ventricular remodeling and incident heart failure. In addition, favorable pleiotropic effects and adverse effects of proton pump inhibitors (PPIs) on cardiovascular disease have also been reported. We examined the associations of acid suppressive therapy using H2RAs or PPIs with cardiac mortality in patients with heart failure.
In total, 1191 consecutive heart failure patients were divided into 3 groups: a non-acid suppressive therapy group (n=363), an H2RA group (n=164), and a PPI group (n=664). In the follow-up period (mean 995 days), 169 cardiac deaths occurred. In the Kaplan-Meier analysis, cardiac mortality was significantly lower in the PPI group than in the H2RA and non-acid suppressive therapy groups (11.0% versus 21.3% and 16.8%, respectively; log-rank =0.004). In the multivariable Cox proportional hazards analysis, use of PPIs, but not H2RAs, was found to be an independent predictor of cardiac mortality (PPIs: hazard ratio 0.488, =0.002; H2RAs: hazard ratio 0.855, =0.579). The propensity-matched 1:1 cohort was assessed based on propensity score (H2RAs, n=164; PPIs, n=164). Cardiac mortality was significantly lower in the PPI group than in the H2RA group in the postmatched cohort (log-rank =0.025). In the Cox proportional hazards analysis, the use of PPIs was a predictor of cardiac mortality in the postmatched cohort (hazard ratio 0.528, =0.028).
PPIs may be associated with better outcome in patients with heart failure.
最近有报道称,组胺H受体拮抗剂(H2RAs)与心室重塑受损及新发心力衰竭有关。此外,也有关于质子泵抑制剂(PPIs)对心血管疾病的有利多效性作用和不良反应的报道。我们研究了使用H2RAs或PPIs进行抑酸治疗与心力衰竭患者心脏死亡率之间的关联。
总共1191例连续入选的心力衰竭患者被分为3组:非抑酸治疗组(n = 363)、H2RA组(n = 164)和PPI组(n = 664)。在随访期(平均995天)内,发生了169例心脏死亡。在Kaplan-Meier分析中,PPI组的心脏死亡率显著低于H2RA组和非抑酸治疗组(分别为11.0%、21.3%和16.8%;对数秩检验P = 0.004)。在多变量Cox比例风险分析中,发现使用PPIs而非H2RAs是心脏死亡率的独立预测因素(PPIs:风险比0.488,P = 0.002;H2RAs:风险比0.855,P = 0.579)。基于倾向评分评估了倾向匹配的1:1队列(H2RAs组,n = 164;PPIs组,n = 164)。在匹配后队列中,PPI组的心脏死亡率显著低于H2RA组(对数秩检验P = 0.025)。在Cox比例风险分析中,使用PPIs是匹配后队列中心脏死亡率的预测因素(风险比0.528,P = 0.028)。
PPIs可能与心力衰竭患者更好的预后相关。